Clinical Trials Sponsored by HRA Pharma

Total 8736 results

UCB Pharma

Completed

A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN).

Postherpetic Neuralgia
Zealand Pharma

Active, not recruiting

A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants

Overweight | Healthy Volunteers | Obese

Germany
LEO Pharma

Completed

A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis

Stable Plaque Psoriasis

China
Advicenne Pharma

Terminated

Study Evaluating Subjects With Distal Renal Tubular Acidosis

Distal Renal Tubular Acidosis

United States, Canada
Advicenne Pharma

Withdrawn

Extension Study in Primary Distal Renal Tubular Acidosis

Acidosis, Renal Tubular

United States
LEO Pharma

Active, not recruiting

Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

Atopic Dermatitis

United States, Belgium, Canada, Czechia, France, Germany, Italy, Japan, Poland, Spain, United Kingdom
Longbio Pharma

Active, not recruiting

A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects

Myelodysplastic Syndrome (MDS)

China
Inventiva Pharma

Active, not recruiting

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus (LEGEND)

Diabetes Mellitus, Type 2 | NASH - Nonalcoholic Steatohepatitis

United States, Belgium, France, Netherlands, United Kingdom
Lumos Pharma

Active, not recruiting

Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial) (OraGrowtH210)

Growth Hormone Deficiency

United States, Australia, Israel, New Zealand, Poland, Ukraine
LEO Pharma

Terminated

Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab (COBRA)

Psoriasis | Plaque Psoriasis | Psoriasis Vulgaris

Belgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
UCB Pharma

Completed

A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy

Epilepsy, Partial
Athira Pharma

Active, not recruiting

ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease (LIFT-AD)

Alzheimer Disease | Dementia of Alzheimer Type

United States
Zealand Pharma

Completed

A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United States, United Kingdom, Germany, Israel
Kiomed Pharma

Active, not recruiting

Evaluation of Performance and Safety of KIO015 in Face Skin Hydration Improvement (PLUM)

Skin Quality

France
Lumos Pharma

Active, not recruiting

PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212) (OraGrowtH212)

Growth Hormone Deficiency

Chile
UCB Pharma

Completed

Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.

Painful Diabetic Neuropathy

Russian Federation, Austria, Belgium, Bulgaria, Czechia, Finland, France, Germany, Hungary, Italy, Poland, Romania, Serbia, Spain, United Kingdom
LEO Pharma

Completed

Tralokinumab Administered With Device A in Adults and Adolescents With Moderate-to-severe Atopic Dermatitis (INJECZTRA)

Atopic Dermatitis

United States
LEO Pharma

Completed

An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

Atopic Dermatitis

United States, Canada, Germany, Poland
Ellipses Pharma

Withdrawn

EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

Gastric Cancer | Small-cell Lung Cancer

China, Korea, Republic of, Taiwan
UCB Pharma

Completed

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults

Unverricht-Lundborg Disease

United States, Canada, Finland, France, Israel, Russian Federation, Serbia, Tunisia
LEO Pharma

Completed

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

Atopic Dermatitis

United States, Belgium, Canada, Australia, France, Germany, Japan, Netherlands, Poland, United Kingdom
Amryt Pharma

Active, not recruiting

Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)

Homozygous Familial Hypercholesterolaemia (HoFH)

Germany, Israel, Italy, Saudi Arabia, Spain, Tunisia
AlzeCure Pharma

Completed

ACD440 Gel in Peripheral Neuropathic Pain

Peripheral Neuropathic Pain

Sweden
Anji Pharma

Suspended

Investigational Study of Delayed Release Metformin (DREAM-T2D)

Diabetes Mellitus, Type 2

Spain, United States, Canada, Hungary, Brazil, Czechia, Poland, Bulgaria
LEO Pharma

Completed

Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema

Chronic Hand Eczema

Germany
Zealand Pharma

Completed

A First-in-human Study Looking at the Safety of ZP8396 and How it Works in the Body of Healthy Trial Participants

Overweight | Healthy Volunteers

Germany
Saffron Pharma

Completed

Efficacy and Safety of New Mometasone Furoate Nasal Spray Formulation in Acute Rhinosinusitis Patients: A Randomized Clinical Trial

Acute Rhinosinusitis

Pakistan
LEO Pharma

Completed

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5) (ECZTRA 5)

Atopic Dermatitis

United States, Canada
UCB Pharma

Completed

Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures (BRITE)

Epilepsy

United States, Czechia, Germany, Poland, Austria, Belgium, Brazil, Bulgaria, Canada, Estonia, Finland, France, Hong Kong, Hungary, India, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Netherlands, Puerto Rico, Russian Federation and more
LEO Pharma

Completed

A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

Atopic Dermatitis

United States
Anji Pharma

Completed

A Phase 1 Study of ANJ900 Chinese Healthy Subjects

Healthy

China
PLx Pharma

Completed

Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects

Gastroduodenal Ulceration

United States
Kiadis Pharma

Terminated

Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer (HATCY)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States, Canada, Netherlands, Israel, Germany, United Kingdom, Belgium, Italy, Sweden, Croatia, Spain, France, Portugal
Genoscience Pharma

Terminated

Study of GNS561 in Patients With Liver Cancer

Hepatocellular Carcinoma | Cholangiocarcinoma, Intrahepatic

France, United States, Belgium
PLx Pharma

Completed

Randomized, Crossover Bioequivalence Study of PL-ASA Versus Immediate Release Aspirin in Healthy Volunteers.

Bioequivalence

United States
LEO Pharma

Completed

Tacrolimus Blood Levels After Topical Application of Tacrolimus on Healthy Skin

Healthy

Germany
GamaMabs Pharma

Completed

Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers

Colorectal Cancer

Belgium, Czechia
GamaMabs Pharma

Completed

First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers

Neoplasm, Gynecologic

France, Belgium, United Kingdom
LEO Pharma

Completed

A Trial to Evaluate the Effect of Delgocitinib on the Heart Rhythm of Healthy People

Healthy Volunteers

United Kingdom
Code Pharma

Completed

Study of Codivir in Patients With COVID-19 (Codivir)

Covid19

Brazil
Pharma VAM

Unknown

Clinical Study in the Treatment of Patients With COVID-19

COVID-19

Russian Federation
LEO Pharma

Terminated

Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis

Disseminated Intravascular Coagulation
Kukje Pharma

Completed

[KSR-001-P01]Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristic of KSR-001

Dry Eye Syndromes

Korea, Republic of
LEO Pharma

Completed

Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib Cream

Healthy Volunteers

Germany
Zealand Pharma

Completed

A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.

Healthy

Netherlands
Zealand Pharma

Completed

A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

Hypoglycemia | Diabetes Mellitus, Type 1

Canada, United States, Austria, Germany
LEO Pharma

Completed

Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis

Actinic Keratosis

United States
Kiadis Pharma

Completed

Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

Canada, Belgium, Germany, Croatia, United Kingdom, Portugal
LEO Pharma

Completed

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

Chronic Hand Eczema

United States, Germany, Denmark
LEO Pharma

Completed

Body PSOriasis: Long-term Relapse CONTROL (PSO-CONTROL)

Psoriasis Vulgaris

Russian Federation

3

Subscribe